Cellulose is the most abundant organic polymer in the world. It is the primary compound in the cell walls of green plants, and is typically used to make paper and cardboard.
At the VTT Technical Centre of Finland, a state owned research and development non-profit, scientists have used nano-structured cellulose to make a 3D printable material.
The nanocellulose paste is now in development to make smart-dressings that heal and monitor skin wounds.
For much of human history, living up to a ripe old age was seen as a gift from the gods, an aberration, or just the product of sheer luck. Given that up to the beginning of the twentieth century many of us succumbed to disease at an early age, being extremely fortunate to live anywhere past the age of forty, it should be no surprise that living a long life is still beatified today as something akin to winning the lottery.
Even when confronted with the galloping pace of scientific advances in human longevity, our historical sensibilities have led us to take a defeatist stance towards the subject: “Even if longevity interventions become available during my lifetime, I am already too late to take advantage of them, so why bother?”
Indeed, this hesitation to see human life extension as a real possibility in our lifetime, dismissing it as a dream belonging to the realms of science fiction[1] and futuristic utopias[2] is not an uncommon one, and as long as tangible rejuvenation therapies do not become available, we will feel validated in our pragmatism.
My new story for my #transhumanism column at Psychology Today on Direct Neurofeedback:
Transhumanism—the movement of using science and technology to improve the human being—covers many different fields of research. There are exoskeleton suits to help the disabled; there are stem cell treatments to cure disease; there are robots and AI to perform human chores. The field is wide open and booming as humanity uses more and more tech in its world.
It’s not that often I get to participate directly in these radical technologies, but I did so recently when Grant Rudolph, Clinical Director at Echo Rock Neurotherapy in Mill Valley, California invited me to try his Direct Neurofeedback techniques. Via his computer and EEG wire hookups, Mr. Rudolph echoed my brainwave information back into my head at an imperceptible level. I did two sessions of Direct Neurofeedback.
At first, I was skeptical that I’d even feel anything since the EEG information can’t be detected by the skin as a sensation, but within five minutes of having the wires stuck onto my forehead, I began feeling different. I can compare it to a light dose of a recreational drug: I felt happy, content, and worry-free. I also felt more introspective than normal. The feedback only took a few seconds, and after about 15 minutes, I seemed to notice the world’s colors were sharper and my hearing was more acute. The heightened awareness and calming effect lasted about 24 hours and then most of it gradually wore off. Some of the clarity must still be working, because getting things done sometimes still seems easier. I’m told that continued sessions would make this state of clarity my new norm.
At well over $150,000 per appliance, the Volta GPU based DGX appliances from Nvidia, which take aim at deep learning with framework integration and 8 Volta-accelerated nodes linked with NVlink, is set to appeal to the most bleeding edge of machine learning shops.
Nvidia has built its own clusters by stringing several of these together, just as researchers at Tokyo Tech have done with the Pascal generation systems. But one of the first commercial customers for the Volta based boxes is the Center for Clinical Data Science, which is part of the first wave of hospitals set to use deep learning for MR and CT image analysis.
The center, which is based in Cambridge, Massachusetts, has secured a whopping four DGX-1 Volta appliances, which sport the latest GPUs with eight per node with the NVlink interconnect. The Next Platform talked with Neil Tenenholtz, senior data scientist at the center, about where deep learning will yield results for hospitals and medical research and about their early experiences with the four machines.
The new self-propelled, cancer-seeking bacteriobot swims right into the tumor and zaps it with a deadly payload of cancer drugs.
The recently perfected #bacteriobot holds ‘a lot of promise’ in treating #cancer says a physician. Cancer patients at a hospital in Montreal may be the first to be treated with these #nanorobots built out of bacteria.
Summary: The recently perfected bacteriobot holds ‘a lot of promise’ in treating cancer says a physician. Cancer patients at a hospital in Montreal may be the first to be treated with nanorobots built out of bacteria. The new self-propelled, cancer-seeking bacteriobot swims right into the tumor and zaps it with a deadly payload of cancer drugs. [Cover image: Getty Images/iStock.]
Google’s Futurist Ray Kurzweil once said that within decades, we will have nanobots, swimming through our veins keeping us healthy. The tiny robots will keep us healthy by correcting DNA errors, removing toxins, extending our memories and zapping cancer. The Futurist said that back in 2007, and his prophecy is becoming a reality, at least in the treatment of cancer.
Years spent developing bacteria-based nanobots are finally bearing fruit, and thanks to progress made by a physician at the Jewish General Hospital (JGH) in Montreal, cancer patients may be the first to be treated with tumor-killing nanorobots. The JGH doctors are using a newly-developed self-propelled, cancer-seeking nanorobot built out of bacteria and referred to as a bacteriobot, an amalgam of the words bacteria and nanorobot.
Full Interview ► https://goo.gl/PvUjjU
Michael B. Fossel, M.D., Ph.D. (born 1950, Greenwich, Connecticut) was a professor of clinical medicine at Michigan State University and is the author of several books on aging, who is best known for his views on telomerase therapy as a possible treatment for cellular senescence. Fossel has appeared on many major news programs to discuss aging and has appeared regularly on National Public Radio (NPR). He is also a respected lecturer, author, and the founder and former editor-in-chief of the Journal of Anti-Aging Medicine (now known as Rejuvenation Research).
Prior to earning his M.D. at Stanford Medical School, Fossel earned a joint B.A. (cum laude) and M.A. in psychology at Wesleyan University and a Ph.D. in neurobiology at Stanford University. He is also a graduate of Phillips Exeter Academy. Prior to graduating from medical school in 1981, he was awarded a National Science Foundation fellowship and taught at Stanford University.
In addition to his position at Michigan State University, Fossel has lectured at the National Institute for Health, the Smithsonian Institution, and at various other universities and institutes in various parts of the world. Fossel served on the board of directors for the American Aging Association and was their executive director.
Fossel has written numerous articles on aging and ethics for the Journal of the American Medical Association and In Vivo, and his first book, entitled Reversing Human Aging was published in 1996. The book garnered favorable reviews from mainstream newspapers as well as Scientific American and was published in six languages. A magisterial academic textbook on by Fossel entitled Cells, Aging, and Human Disease was published in 2004 by Oxford University Press.
Since his days as a teacher at Stanford University, Fossel has studied aging from a medical and scientific perspective with a particular emphasis on premature aging syndromes such as progeria, and since at least 1996 he has been a strong and vocal advocate of [telomerase therapy]] as a potential treatment of age-related diseases, disorders, and syndromes such as progeria, Alzheimer’s disease, atherosclerosis, osteoporosis, cancer, and other conditions. However, he is careful to qualify his advocacy of telomerase therapy as being a potential treatment for these conditions rather than a “cure for old age” and a panacea for age-related medical conditions, albeit a potential treatment that could radically extend the maximum human life span and reverse the aging process in most people. Specifically, Fossel sees the potential of telomerase therapy as being the single most effective point of intervention in a wide variety of age-related medical conditions. His new book, The Telomerase Revolution, (BenBella, 2015) gives a careful explanation of aging, age-related diseases, and the prospects for intervention, including upcoming human trials.
Shai Ben-David, Professor at the University of Waterloo, gave Machine Learning Course composed of 23 Lectures (CS 485/685) at the University of Waterloo on Jan 14, 2015…
Machine learning is the science of getting computers to act without being explicitly programmed. In the past decade, machine learning has given us self-driving cars, practical speech recognition, effective web search, and a vastly improved understanding of the human genome. Machine learning is so pervasive today that you probably use it dozens of times a day without knowing it. Many researchers also think it is the best way to make progress towards human-level AI.
Shai Ben-David holds a PhD in mathematics from the Hebrew University is Jerusalem. He has held postdoctoral positions at the University of Toronto in both the Mathematics and CS departments. He was a professor of computer science at the Technion in Haifa, Israel. Ben-David has held visiting positions at the Australian National University and Cornell University, and since 2004 has been a professor of computer science at the University of Waterloo in Canada.
The US is in a opioid addiction crisis that has been described as a national epidemic by health officials. Each day 91 people die after overdosing on the drugs, according to the Centers for Disease Control and Prevention. More Americans now die from drug overdoses than in car accidents or from gun violence put together, and more than 2.6m are addicted to opioids, according to CDC figures.
Health insurance system is partly to blame for the epidemic that is costing companies $18bn a year.
Researchers at the Institute of Molecular Biology (IMB) in Mainz, Germany, have made a breakthrough in understanding the origin of the ageing process. They have identified that genes belonging to a process called autophagy — one of the cells most critical survival processes — promote health and fitness in young worms but drive the process of ageing later in life. This research published in the journal Genes & Development gives some of the first clear evidence for how the ageing process arises as a quirk of evolution. These findings may also have broader implications for the treatment of neurodegenerative disorders such as Alzheimer’s, Parkinson’s, and Huntington’s disease where autophagy is implicated. The researchers show that by promoting longevity through shutting down autophagy in old worms there is a strong improvement in neuronal and subsequent whole body health.
Getting old, it’s something that happens to everyone and nearly every species on this planet, but the question is, should it? In a recent publication in the journal Genes & Development titled “Neuronal inhibition of the autophagy nucleation complex extends lifespan in post-reproductive C. elegans,” the laboratory of Dr Holger Richly at IMB, has found some of the first genetic evidence that may put this question to rest.
As Charles Darwin explained, natural selection results in the fittest individuals for a given environment surviving to breed and pass on their genes to the next generation. The more fruitful a trait is at promoting reproductive success, the stronger the selection for that trait will be. In theory, this should give rise to individuals with traits which prevent ageing as their genes could be passed on nearly continuously. Thus, despite the obvious facts to the contrary, from the point of evolution ageing should never have happened. This evolutionary contradiction has been debated and theorised on since the 1800s. It was only in 1953 with his hypothesis of antagonistic pleiotropy (AP) that George C. Williams gave us a rational explanation for how ageing can arise in a population through evolution. Williams proposed that natural selection enriches genes promoting reproductive success but consequently ignores their negative effects on longevity.
Nanostructured systems have the potential to revolutionize both preventive and therapeutic approaches for treating cardiovascular disease. Given the unique physical and chemical properties of nanostructured systems, nanoscience and nanotechnology have recently demonstrated the potential to overcome many of the limitations of cardiovascular medicine through the development of new pharmaceuticals, imaging reagents and modalities, and biomedical devices. A recent review offers an outline of critical issues and emerging developments in cardiac nanotechnology.
